We report the case of a teenage boy with thrombocytopenia complicating varicella infection, which responded promptly to treatment with intravenous immunoglobulin therapy. Such treatment is well recognized in the management ofimmune thrombocytopenia, particularly where steroids are contra-indicated, but we have not found any previous case reports of the use of immunoglobulin in this condition.
Introduction
Varicella infection is usually a benign and selflimiting condition in childhood and adolescence; thrombocytopenia is an uncommon complication. Fatal haemorrhage has, however, been reported. ' We describe a case of varicella-induced thrombocytopenia in a 17 year old boy, which responded to treatment with intravenous gammagobulin.
Case report
A previously fit 17 year old boy developed an extensive rash of varicella vesicles with typical distribution. On the 8th day he awoke to find his bed-linen covered with blood spots and noted the presence of fresh haemorrhagic lesions over the oral mucous membranes and the inner eyelids within the conjunctival sac. Most of the vesicles on his body were haemorrhagic. There was no epistaxis, haemoptysis or haematuria and he did not experience headaches or visual symptoms. He was admitted to hospital 2 days later. Examination showed no bruising or fundal haemorrhage. Results of investigations showed haemoglobin 15.6 g/dl, white cell count 13.5 x 109/l (normal differential count), platelet count 5.0 x 109/l; clotting screen, in particular prothrombin time, was normal. Bone marrow examination showed increased megakaryocytes, but was otherwise normal. Chest X-ray was unremarkable. Subsequent investigations showed normal levels of urea, creatinine, electrolytes, liver enzymes, immunoglobulins IgA, IgE and IgM, anti-nuclear factor, complement C3, C4 and CH 100. The next morning platelets were absent on the blood film.
Treatment was commenced with intravenous gammaglobulin (sandoglobulin) 0.4 g/kg (24 g) daily; because of the long distance from the Regional Blood Transfusion Service platelets were ordered and subsequently transfused, in view of the complete absence of platelets on the film. The response to treatment and the apparently increasing survival of transfused platelets on days 2 and 3, is shown in Figure 1 . Platelet counts were checked immediately before and 60 min after platelet transfusions on days 1-4. Twice daily examination of optic fundi showed that retinal haemorrhages did not develop, and haematuria and other evidence of internal bleeding did not develop either. Within 4 days of starting treatment the platelet count increased to 60 x 109/l and the patient was allowed home. Subsequent platelet counts showed a complete recovery and further complications did not occur.
Discussion
Management of varicella-induced thrombocytopenia is difficult and deaths due to intracranial haemorrhage have been described. Platelet transfusion alone is ineffective because of rapid destruction by platelet auto-antibodies,2 or by other mechanisms of platelet inactivation, lysis or desialization.3 Treatment with corticosteroids might potentiate the viraemia with fatal results,4 although in this case the haemorrhagic development was not obvious until 8 days after the initial rash appeared. Within 48 h of commencement of gammaglobulin, platelet counts started to increase, suggesting that inhibition of platelet destruction was occurring in response to treatment. After 3-4 days release of endogenous platelets into the circulation and their survival was suggested by the rapidly rising platelet count and the appearance of individual platelets on fresh blood films.
Intravenous gammaglobulin has a role in the management of immune-thrombocytopenia in several clinic settings5 and may also be of value in the treatment of the thrombocytopenia of haemorrhagic varicella infection.
